<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134467">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01880879</url>
  </required_header>
  <id_info>
    <org_study_id>Pro-HOPE</org_study_id>
    <nct_id>NCT01880879</nct_id>
  </id_info>
  <brief_title>A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment</brief_title>
  <acronym>Pro-HOPE</acronym>
  <official_title>A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kinhely Bio-tech Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kinhely Bio-tech Co.,Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      research topic:helios After registration of clinical research bidders:kinhely bio-tech
      Co.Ltd study design:A prospective single treatment group multicenter clinical study Number
      of patients:Included in the subjects of 800 cases Main research purpose:Evaluation of safety
      and effectiveness Mainly studies the finish:1 year target lesion of the failure

      Inclusion criteria :

      one:Gender not limited at the age of 18 to 80 two:myocardial ischemia or angina symptoms of
      coronary artery disease three:A narrow is less than 50% treated with stents four:Comply with
      the instructions five:Voluntarily signed the informed consent form exclusion criteria:
      one:Pregnant women two:cardiac shock three:Against a suppository medicines or allergies
      four:Participated in other test research in the first 6 months five:Within 6 months after
      PCI plans to accept non cardiac surgery six:Non-compliant patient Follow-up time:A month for
      6 months and 9 months to 1 year to 2 years follow-up progress plan:All center within 6
      months after start of complete into the group
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      no desired
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>1 year incidence of target lesion</measure>
    <time_frame>1year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Target blood vessels caused by cardiac death and myocardial infarction and ischemia driven overall incidence of target lesion revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiac death Target blood vessels caused by myocardial infarction Ischemia driven target lesion revascularization of 1 year and 2 years,MACE, Stent thrombosis events,clinical success.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Death and myocardial infarction and thromboembolism events and hospitalizations and the incidence of major adverse cardiac events as the standard for safety evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 years, the incidence of various combination of the pathological changes of failure</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cardiac death drive target blood vessels lead to myocardial infarction and ischemia of the incidence of target lesion revascularization</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rehospitalization rate</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Stent placement in patients with the incidence of hospitalized again</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>helios stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the group with helios stent implanted</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>helios stent</intervention_name>
    <description>the group with helios stent implanted</description>
    <arm_group_label>helios stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any age 18 to 80 sex Myocardial ischemia or angina pectoris of coronary artery
             disease An application stents diameter stenosis greater than 50% Comply with the
             instructions Voluntarily signed the informed consent form

        Exclusion Criteria:

          -  Pregnant women cardiac shock Intolerance to antithrombotic therapy or allergies 6
             months prior to the start of the study involved in other studies Within 6 months
             after PCI plans to accept non cardiac surgery Non-compliant patient
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yan chai hospital affiliated to Shanghai jiaotong university school of medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>qi lu, chairman</last_name>
      <phone>+86-021-68383364</phone>
      <phone_ext>68383006</phone_ext>
      <email>rjluqi@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>ben he, chairman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Zhang T, Shen L, Hu L, He B. Optimal Duration of Dual-Antiplatelet Therapy Following Drug-Eluting Stent Implantation: A Meta-Analysis. J Clin Pharmacol. 2012 May 25. [Epub ahead of print] PubMed</citation>
    <PMID>22639432</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>June 20, 2013</lastchanged_date>
  <firstreceived_date>May 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>PCI</keyword>
  <keyword>stent</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
